Mechanism of action<unk>  targets the IL-23 subunit alpha (p19 subunit) preventing it from binding to cell receptors that would otherwise be activated by its presence. Pharmacokinetics * Cmax 8.09 µg/mL * tmax 5.5 days * volume of distribution 13.5 L * apparent clearance 0.516 L/day
Guselkumab
Ustekinumab
Emapalumab
Olaratumab
Evolocumab
Dupilumab
Tralokinumab
Alirocumab